drug
as of 2026-07-01SLV-313 SR
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Wyeth is now a wholly owned subsidiary of Pfizer
2 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
2
Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients
NCT00581243Phase 1Terminated
Study Evaluating Multiple Ascending Dose in Schizophrenia Patients
NCT00620568Phase 1Terminated
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
trial
indication
indication
indication